Our Clinical Focus

  • Our bioorthogonal linker chemistries have potential utility in many different disease settings. We have focused initially on addressing major unmet needs and intractable, difficult to target biology for the treatment of Cancer.

  • pipeline

  • The FDA approval of first generation ADC’s such as Kadcyla and the promising early data from clinically tested SMDCs such as Vintafolide has demonstrated the value of these new drug modalities for treating advanced Cancer. It has also exposed opportunities for us to improve on these agents (and others already in development). Our first proprietary SMDC programs will utilize our exquisitely tunable linkers and payload cassettes to deliver more payload, more quickly to a patient’s tumor. There is a lot known about the susceptibility of different tumors to different classes of cytotoxic drugs and we believe that these new BlinkBio SMDCs will be able to enhance the degree of anti-cancer activity achieved while sparing the patient from the worst impact of the toxic side effects of these drugs – allowing us to advance this exciting new technology for the treatment of many cancers, most notably, difficult to treat and highly prevalent solid tumors such as advanced lung and ovarian cancer.

    Our more complex and highly innovative reversible linker technology is best suited to important intracellular targets that have proven to be intractable to both established and exploratory therapeutic approaches. Two such targets, which are involved in either driving tumor growth or suppressing it, are the oncogene MYC and the tumor suppressor gene p53, two enormously important targets in cancer research that have thwarted researchers for decades. Together with our collaborative partners we believe this technology may offer a unique avenue for the direct targeting of these proteins and the subsequent development of targeted therapies directed towards the treatment of the hundreds of thousands of cancer patients whose tumors possess either abnormal levels or mutated forms of MYC or p53.